New hope for Tough-to-Treat lung cancer: early trial tests powerful drug duo
NCT ID NCT07382726
Summary
This early-stage study is testing whether combining two drugs works better for people with advanced lung cancer that has a specific genetic change (KRAS G12C) and has stopped responding to previous targeted treatments. The main goal is to check if the combination is safe and tolerable for patients. Researchers will enroll about 18 adults whose cancer has continued to grow despite standard KRAS inhibitor therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.